Primary Care Companion for CNS Disorders

Case Report November 17, 2026

Psychotic Symptoms Secondary to Lisdexamfetamine: A Clinical Case

; ; ; ;

Prim Care Companion CNS Disord 2026;28(6):26cr04241

Prescription of psychostimulants (methylphenidate, lisdexamfetamine, modafinil) for the treatment of various conditions (narcolepsy, attention-deficit/hyperactivity disorder [ADHD], among others) has been recently increasing worldwide. These medications should be prescribed carefully due to significant side effects.

The relation between psychosis development and psychostimulants is relevant and has been on the radar of the scientific community. These drugs have been implicated in the development of psychotic symptoms in patients with narcolepsy1 and ADHD. Most studies conducted have been in patients with narcolepsy and not ADHD or other diagnoses.

A direct relationship between the use of prescription psychostimulants and the onset of a first psychotic episode has not been established. Still, there are some hypotheses described that could justify this relationship. First, it is possible that the pharmacologic effects of the psychostimulant itself cause psychotic symptoms in a patient without psychosis history: increased levels of dopaminergic and noradrenergic neurotransmitters, like what happens in schizophrenia, according to the dopaminergic theory.2 The mechanism for the development of psychotic symptoms secondary to psychostimulants also appears to be dose dependent.

There is also a second scenario. A psychotic episode secondary to the use of psychostimulants may not occur directly because of the drug; it can occur due to the existence of a previously undiagnosed psychotic or mood disorder or one that exists comorbidly with the condition for which the psychostimulant was prescribed. We describe the case of a patient who suddenly developed psychotic symptoms for the first time in her life after initiating lisdexamfetamine.

Case Report

A 32-year-old woman came to an outpatient psychiatric unit suspecting that she had ADHD. This diagnosis was confirmed after a thorough assessment and administration of the Diagnostic Interview for ADHD in Adults questionnaire. She had no previous personal or family history of psychiatric disorders. Her past medical history was unremarkable. General blood and urine analyses showed no abnormalities, and the electrocardiogram was normal.

She started lisdexamfetamine 30 mg and was assessed 2 weeks later. According to the patient, 2 nights before the reevaluation appointment, she started hearing her thoughts out loud, as if they were coming from an external person, and felt suspicious. Furthermore, she felt that someone might be speaking about her and that she was the center of attention when walking in the street. She retained some insight, doubting the veracity of the experiences she had.

On psychiatric examination, she presented with disorganized speech, auditory hallucinations, and autoreferential delusions. Partial insight was retained.

The patient had no history of substance use. Current abstinence was confirmed by a urine toxicology screen, indicating that cocaine, marijuana, alcohol, or any other illicit substances were present. A new analytic evaluation was performed and showed no abnormalities. Lisdexamfetamine was discontinued, and she showed no psychotic or affective symptoms, with full insight for the described experiences.

Discussion

Considering the clinical presentation, the patient fulfills DSM-5 and ICD-10 criteria for a substance-induced psychosis diagnosis.3,4 In our case, the patient developed psychotic symptoms secondary to lisdexamfetamine intake with full remission after discontinuation.

Most case reports of psychotic symptoms induced by psychostimulants report variable positive psychotic symptoms, with a predominance of persecutory and paranoid delusions, cenesthetic hallucinations, or acoustic-verbal hallucinations.1 In some cases, manic-like symptoms may emerge.5

Given the above, before initiating treatment with a stimulant, collection of the patient’s clinical history is of utmost importance. This allows for the assessment of whether there is a higher risk of vulnerability to developing a psychotic episode secondary to the use of a psychostimulant. If such vulnerability seems to exist, it should prompt a reevaluation of the therapeutic option for the patient and avoidance of the prescription of a psychostimulant. If necessary for the condition, stricter clinical monitoring should be carried out, and the psychostimulant should be discontinued immediately if needed.6

Our patient did not have an increased risk of developing psychotic symptoms, yet they emerged despite the lack of vulnerability. Therefore, it is crucial to closely monitor the psychiatric condition, even in the absence of evident vulnerability and to be vigilant for subtle signs of psychopathology that could signal the onset of a psychotic episode.

Article Information

Published Online: November 17, 2026. https://doi.org/10.4088/PCC.26cr04241
© 2026 Physicians Postgraduate Press, Inc.
Prim Care Companion CNS Disord 2026;28(6):26cr04241
Submitted: March 28, 2026; accepted June 11, 2026.
To Cite: Romão J, Ribeiro M, Revez J, et al. Psychotic symptoms secondary to lisdexamfetamine: a clinical case.
Prim Care Companion CNS Disord 2026;28(6):26cr04241.
Author Affiliations: Psychiatry and Mental Health Department, Unidade Local de Saúde de Santa Maria, Lisbon, Portugal (Romão, Ribeiro, Revez, Silva, Saraiva); Faculty of Medicine, University of Lisbon, Lisbon, Portugal (Romão, Ribeiro, Saraiva).
Corresponding Author: Joana Romão, MD, Psychiatry and Mental Health Department Unidade Local de Saúde de Santa Maria. Lisbon, Portugal ([email protected]).
Financial Disclosure: None.
Funding/Support: None.
Patient Consent: Consent was received from the patient to publish the case report, and information, including dates, has been de-identified to protect patient anonymity.

  1. Berman SM, Kuczenski R, McCracken JT, et al. Potential adverse effects of amphetamine treatment on brain and behavior: a review. Mol Psychiatry. 2009;14(2):123Y142–142.
  2. Auger RR, Goodman SH, Silber MH, et al. Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: a case-control study. Sleep. 2005;28(6):667–672. PubMed CrossRef
  3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th ed). American Psychiatric Association; 2013.
  4. World Health Organization. ICD-10: International Statistical Classification of Diseases and Related Health Problems: Tenth Revision, 2nd ed. World Health Organization; 2004.
  5. Ross RG. Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder. Am J Psychiatry. 2006;163(7):1149–1152. PubMed CrossRef
  6. Kraemer M, Uekermann J, Wiltfang J, et al. Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature. Clin Neuropharmacol. 2010;33(4):204–206. PubMed CrossRef
Buy PDF for $40

Please sign in or purchase this PDF for $40.